investment analyst

As my regular readers know, I’ve been a big fan of John Bogle, the founder and now-retired chairman of The Vanguard Group, for many years. This spring, I got to meet him in person for the first time, and I learned a lot.

This is the second article based on my 90-minute conversation. (You’ll find the first article here).

Vanguard’s mutual funds are well known for their low expenses which of course is a very good thing for investors. Many of the company’s most popular funds charge investors less than 0.2% a year, while the average equity fund charges more than 1%.

investment analyst: Novo Nordisk A/S(NVO)

Advisors’ Opinion:

  • [By Keith Speights]

    Eisai (NASDAQOTH:ESALY), Novo Nordisk (NYSE:NVO), and Roche Holding Ltd. (NASDAQOTH:RHHBY) fit that description well. Each of these companies markets obesity drugs, but each also sells a broad array of other products with multiple pipeline candidates potentially on the way. Here’s why Eisai, Novo Nordisk, and Roche rank as the three best obesity-drug stocks to buy in 2017.

  • [By Paul Ausick]

    Novo Nordisk A/S (NYSE: NVO) dropped about 1.5% on Friday to post a new 52-week low of $32.35 after closing at $32.84 on Thursday. The stock’s 52-week high is $59.00. Volume of about 3.4 million was close to the daily average of around 3.9 million shares. The drug maker had no specific news.

  • [By Brian Orelli]

    Global Blood Therapeutics (NASDAQ:GBT) is up 20% at 3:42 p.m. EST after Reuters reported that Novo Nordisk (NYSE:NVO) has approached the biotech about a potential acquisition.

  • [By James E. Brumley]

    When most investors think of diabetes stocks, names like Novo Nordisk A/S (ADR) (NYSE:NVO) and MannKind Corporation (NASDAQ:MNKD) come to mind. And well they should. Novo Nordisk is the biggest insulin company in the world, and while MannKind is relatively small, it’s a name that turns heads simply because it came up with an inhalable insulin that – after a slow start – is getting a little traction.

    In both cases though, the paradigm is the same one that was first used decades ago. That is, if a person isn’t making their own insulin, then it must be introduced externally. What if instead a diabetic’s glucose levels could be controlled by turning on the cells in their body responsible for processing that sugar? That’s the approach Cell MedX Corp (OTCMKTS:CMXC) is taking, using a relatively new but very compelling science.

    While chemical-based manufactured pharmaceuticals were largely the core of healthcare for well over the past century, it’s become clear that our bodies – right down to our cells – are also electrical in nature. Not only do they produce it, they need it to function properly. The FDA has even recently approved a therapeutic device that delivers mild electrical currents to and through an individual’s body as a means of treating pain. This “electromedicine” has also shown a certain degree of efficacy as a treatment for several illnesses, including cancer. Specifically, electrical currents have been demonstrated to force pleomorphic cancer microbes into hibernation, essentially making a cancerous cell a normal, healthy cell again. So, using an electrical current as a means of therapy for diabetics isn’t far-fetched at all. Indeed, it’s quite brilliant.

    As for how Cell MedX is using the idea, it’s actually quite simple. The device is called an eBalance. At first glance it just looks like another ordinary tablet computer. A closer inspection of the e-Balance device, however, makes it clear that it’s not just another tablet. It’

  • [By Peter Graham]

    A long term performance chart shows MannKind Corporation having once been a highflyerwhile the performance of large cap insulin and diabetes stockNovo Nordisk A/S (NYSE: NVO) has fallen off and small cap Insulet Corporation (NASDAQ: PODD) has actually performed better:

investment analyst: V.F. Corporation(VFC)

Advisors’ Opinion:

  • [By Jeremy Bowman]

    The North Face, in particular, seems like a cautionary tale. The outdoor gear and apparel maker had its IPO in 1996. By 1999 sales were falling and the company put up a $100 million loss. In 2000,VF Corporation(NYSE:VFC) acquired it for just $25.4 million, despite $238 million in sales and a once-popular brand. Today, under the guidance of VF Corp, The North Face now has more than $2 billion in annual sales.

  • [By Leo Sun]

    VF Corp. (NYSE:VFC) owns a massive portfolio of apparel companies, including The North Face, Timberland, Wrangler, Lee, and Vans. It’s raised its dividend annually for over four decades — making it an elite “dividend aristocrat” which has boosted its payout for at least 25 straight years. VF currently pays a forward yield of 3.1%, which is supported by a payout ratio of 55%. The stock trades at 21 times earnings.

  • [By Lisa Levin] Gainers
    Aimmune Therapeutics Inc (NASDAQ: AIMT) shares jumped 35 percent to $34.64 in response to failed DBVT peanut allergy trial.
    Exactech, Inc. (NASDAQ: EXAC) shares surged 30.9 percent to $41.88 after the company agreed to be acquired by TPG Capital for $42 per share in cash.
    Dextera Surgical Inc (NASDAQ: DXTR) shares climbed 27.6 percent to $0.238 after surging 40.48 percent on Friday.
    Petmed Express Inc (NASDAQ: PETS) jumped 21.8 percent to $44.73 as the company reported better-than-expected Q2 results.
    SenesTech Inc (NASDAQ: SNES) shares surged 21.7 percent to $1.95 after the company disclosed that Univar will be marketing and selling ContraPest.
    Yulong Eco-Materials Ltd (NASDAQ: YECO) shares gained 18.3 percent to $0.560.
    One Horizon Group Inc (NASDAQ: OHGI) shares rose 18 percent to $1.18.
    Atossa Genetics Inc (NASDAQ: ATOS) shares climbed 18 percent to $0.566. Atossa Genetics is schedule to host a conference call to announce preliminary results from Phase 1 study of oral Endoxifen on October 25, 2017.
    ReneSola Ltd. (ADR) (NYSE: SOL) shares rose 15.3 percent to $2.72
    Renren Inc (NYSE: RENN) shares gained 11.9 percent to $10.71 after gaining 2.68 percent on Friday.
    Kalvista Pharmaceuticals Inc (NASDAQ: KALV) shares rose 11.8 percent to $12.59. KalVista Pharma 13D filing from Longwood Fund showed registration for an 8.7 percent stake.
    Xunlei Ltd (NASDAQ: XNET) shares gained 9.4 percent to $7.20 after surging 25.33 percent on Friday.
    VF Corp (NYSE: VFC) shares surged 7.1 percent to $71.09 after the company reported upbeat earnings for its third quarter and raised its FY2017 guidance.
    CAI International Inc (NYSE: CAI) rose 6.6 percent to $39.70. Cowen & Co. upgraded CAI from Market Perform to Outperform.
    Agenus Inc (NASDAQ: AGEN) shares gained 5.7 percent to $4.58 as the company disclosed that GSK's shingle vaccine received FDA approval.
    Deltic Timber Corp (NYSE: DEL) shares climbed 5.6 percent to $94.11
  • [By Ben Levisohn]

    Today, the Wall Street Journal reported that Kate Spade & Co is considering a sale of the company, following pressure from activist investors given the volatile performance ever since Kate Spade became a mono brand company over 2 years ago. The article cites thatKate Spade has hired an investment bank and has reached out to possible buyers (including other retailers) althoughKate Spade has not responded. This comes at a time when brand houses like VF Corp. (VFC), PVH Corp. (PVH), Hanesbrands (HBI), Michael Kors Holdings (KORS), and Coach have said they are looking to make a branded acquisition, andKate Spade could be one of the strongest candidates. While other brands are seeing negative comps, pulling back on wholesale exposure or restructuring,Kate Spade continues to grow.

investment analyst: News Corporation(NWS)

Advisors’ Opinion:

  • [By Monica Gerson]

    News Corp (NASDAQ: NWS) reported a profit of $506 million, or $0.87 per share for the year ended June 30, versus a year-ago loss of $2.08 billion, or $3.58 per share. Its revenue rose 2.7% to $8.89 billion. However, analysts were expecting earnings of $0.57 per share on revenue of $8.96 billion. News Corp shares fell 1.28% to close at $16.91 on Friday.

investment analyst: American Superconductor Corporation(AMSC)

Advisors’ Opinion:

  • [By William Romov]

    According to S&P Capital IQ, shares of TTOO have an average price target of $5.75, representing 40.24% upside from current levels.

    Penny Stocks to Buy for December 2017, No. 4: American Superconductor Corp. (Nasdaq: AMSC)

    Massachusetts-based American Superconductor Corp. (Nasdaq: AMSC) makes two-megawatt wind turbines under the Windtec Solutions brand. The company also sells products and services to connect electricity-generating equipment with the power grid.

  • [By Lisa Levin] Gainers
    Marathon Patent Group Inc (NASDAQ: MARA) shares surged 30.2 percent to $5.01 after dropping 40.86 percent on Tuesday. Marathon Patent Group filed for sale of 1.85 million shares of common stock by selling stockholders.
    Capricor Therapeutics Inc (NASDAQ: CAPR) shares jumped 17.2 percent to $2.25 after the company reported the FDA clearance of Investigational New Drug application for CAP-1002.
    Rite Aid Corporation (NYSE: RAD) gained 13.2 percent to $2.15 following 16.5 percent rally on Tuesday.
    Photronics, Inc. (NASDAQ: PLAB) shares climbed 11.8 percent to $10.45 after the company reported stronger-than-expected earnings for its fourth quarter.
    China Distance Education Hldgs Ltd (ADR) (NYSE: DL) shares surged 11.3 percent to $8.67. China Distance Education reported Q4 profit of $5.9 million on revenue of $41.7 million.
    Cytokinetics, Inc. (NASDAQ: CYTK) shares gained 11 percent to $8.05 after falling 7.05 percent on Tuesday.
    Ooma Inc (NYSE: OOMA) shares surged 8.5 percent to $10.85 as the company posted strong Q3 results.
    Nuance Communications Inc. (NASDAQ: NUAN) climbed 8 percent to $17.12 after the company reported stronger-than-expected results for its fourth quarter on Tuesday.
    American Superconductor Corporation (NASDAQ: AMSC) surged 7.8 percent to $3.59 after the company reported $8 million in D-VAR system orders.
    Thermon Group Holdings Inc (NYSE: THR) rose 6.3 percent to $24.17. William Blair upgraded Thermon Group from Market Perform to Outperform.
    Domino's Pizza, Inc. (NYSE: DPZ) surged 6.1 percent to $182.88. Nomura upgraded Domino's from Neutral to Buy.
    Xencor Inc (NASDAQ: XNCR) rose 5.9 percent to $21.17. Cantor Fitzgerald initiated coverage on Xencor with an Overweight rating.
    Idera Pharmaceuticals Inc (NASDAQ: IDRA) gained 5.1 percent to $2.28 after the company disclosed that it has been granted FDA Fast Track designation for IMO-2125.
    Regal Entertainment Group (NYSE: RGC) gained 5.1 percent to

investment analyst: ENI S.p.A.(E)

Advisors’ Opinion:

  • [By Dustin Parrett]

    Big Oil stocks are the seven “oil supermajors” that do everything from oil drilling to refining to retail sales. This is a list of the Big Oil companies:

    Big Oil CompanyShare PriceYTDMarket CapExxon Mobil Corp. (NYSE: XOM)$83.44-7.58%$353.13BChevron Co. (NYSE: CVX)$113.56-3.5%$217.62BConocoPhillips Co. (NYSE: COP)$48.21-3.78%$61.42BRoyal Dutch Shell Plc. (NYSE ADR: RDS.A)$52.35-3.82%$221.08BBP Plc. (NYSE ADR: BP)$34.12-8.71%$112.69BTotal SA (NYSE: TOT)$50.26-1.35%$124.6BEni SpA (NYSE: E)$31.51-2.3%$58.69B

    Despite being huge global oil companies, shares of Big Oil stocks are all in the red this year. Those losses have all happened even as the Dow is smashing record highs and trading up 6.4% year to date.

  • [By Dustin Parrett]

    Specifically, the oil supermajors are ExxonMobil Corp. (NYSE: XOM), BP Plc. (NYSE: BP), Chevron Corp. (NYSE: CVX), Royal Dutch Shell Plc. (NYSE ADR: RDS.A), Conoco Phillips (NYSE: COP), Eni SpA (NYSE ADR: E), and Total SA (NYSE ADR: TOT).

  • [By Paul Ausick]

    Reuters reported last week that the company is considering selling its 2,500 service stations in Italy for a tidy 500 million (about $538 million). The rumored buyer is private equity giant Apollo Global Management LLC (NYSE: APO), also rumored to be interested in buying 2,600 Italian service stations from a joint venture between Italy’s Eni SpA (NYSE: E) and Total SA (NYSE: TOT).

Leave a Reply

Your email address will not be published. Required fields are marked *